Impax Asset Management Group plc Cuts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Impax Asset Management Group plc trimmed its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 53.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 2,613 shares of the biopharmaceutical company’s stock after selling 3,030 shares during the quarter. Impax Asset Management Group plc’s holdings in Regeneron Pharmaceuticals were worth $1,861,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. IFP Advisors Inc boosted its holdings in shares of Regeneron Pharmaceuticals by 17.2% during the 4th quarter. IFP Advisors Inc now owns 368 shares of the biopharmaceutical company’s stock valued at $262,000 after acquiring an additional 54 shares during the last quarter. Y Intercept Hong Kong Ltd boosted its holdings in shares of Regeneron Pharmaceuticals by 22.3% during the 4th quarter. Y Intercept Hong Kong Ltd now owns 11,525 shares of the biopharmaceutical company’s stock valued at $8,210,000 after acquiring an additional 2,100 shares during the last quarter. Forvis Mazars Wealth Advisors LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 1.3% during the 4th quarter. Forvis Mazars Wealth Advisors LLC now owns 3,255 shares of the biopharmaceutical company’s stock valued at $2,319,000 after acquiring an additional 41 shares during the last quarter. Howard Capital Management Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 3.0% in the 4th quarter. Howard Capital Management Inc. now owns 3,102 shares of the biopharmaceutical company’s stock worth $2,210,000 after purchasing an additional 89 shares during the period. Finally, Sigma Planning Corp lifted its stake in shares of Regeneron Pharmaceuticals by 91.2% in the 4th quarter. Sigma Planning Corp now owns 782 shares of the biopharmaceutical company’s stock worth $557,000 after purchasing an additional 373 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently weighed in on REGN shares. Oppenheimer lowered their price objective on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. TD Cowen lowered their price objective on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a research note on Tuesday, February 4th. Wells Fargo & Company lowered their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research note on Friday, January 10th. BMO Capital Markets lowered their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 4th. Finally, Canaccord Genuity Group cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Trading Up 1.4 %

REGN stock opened at $723.47 on Wednesday. The firm has a fifty day moving average price of $698.84 and a 200 day moving average price of $875.48. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $642.00 and a fifty-two week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The firm has a market cap of $79.09 billion, a PE ratio of 18.90, a price-to-earnings-growth ratio of 2.34 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $11.86 earnings per share. Sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.49%. The ex-dividend date of this dividend is Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.